Cholesterol efflux pathways, inflammation, and atherosclerosis

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Immunology

Background:

• Plasma high-density lipoprotein (HDL) levels are inversely correlated with cardiovascular disease (CVD) incidence.
• Mendelian randomization studies and clinical trials have yielded conflicting results regarding the causal link between HDL-cholesterol levels and CVD.
• Recent studies suggest cholesterol efflux capacity of HDL, rather than just HDL-cholesterol levels, is a critical factor in CVD.

Purpose of the Study:

• To investigate the role of HDL cholesterol efflux capacity in cardiovascular disease.
• To elucidate the mechanisms by which cholesterol efflux pathways influence inflammation and atherogenesis.
• To re-evaluate the causal relationship between HDL and CVD.

Main Methods:

• Analysis of large population cohorts.
• Mendelian randomization studies with increased CVD case numbers.
• Investigation of cholesterol efflux pathways in macrophages and atherosclerotic plaques.
• Single-cell RNA sequencing of atherosclerotic plaques.

Main Results:

• Cholesterol efflux capacity of HDL inversely correlates with CVD.
• Cholesterol efflux pathways exert anti-inflammatory and anti-atherogenic effects.
• These pathways suppress hematopoietic stem cell proliferation, macrophage inflammation, and inflammasome activation.
• Defective cholesterol efflux can lead to pro-inflammatory lesional foam cells.

Conclusions:

• HDL's cholesterol efflux capacity is a significant determinant of CVD risk.
• Cholesterol efflux pathways play a crucial role in preventing atherosclerosis by modulating macrophage function and inflammation.
• Understanding these mechanisms offers potential therapeutic targets for CVD prevention and treatment.